Canada · Delayed Price · Currency is CAD HLS Therapeutics Statistics
Total Valuation
TSX:HLS has a market cap or net worth of CAD 111.37 million. The enterprise value is 151.38 million.
| Market Cap | 111.37M |
| Enterprise Value | 151.38M |
Important Dates
The last earnings date was Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:HLS has 30.94 million shares outstanding. The number of shares has decreased by -1.42% in one year.
| Current Share Class | 30.94M |
| Shares Outstanding | 30.94M |
| Shares Change (YoY) | -1.42% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 1.00% |
| Float | 19.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.39 |
| PB Ratio | 1.42 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.32 |
| P/OCF Ratio | 4.30 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.08, with an EV/FCF ratio of 5.87.
| EV / Earnings | n/a |
| EV / Sales | 1.90 |
| EV / EBITDA | 6.08 |
| EV / EBIT | n/a |
| EV / FCF | 5.87 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.05 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | 2.39 |
| Debt / FCF | 2.31 |
| Interest Coverage | -0.92 |
Financial Efficiency
Return on equity (ROE) is -14.07% and return on invested capital (ROIC) is -2.57%.
| Return on Equity (ROE) | -14.07% |
| Return on Assets (ROA) | -2.03% |
| Return on Invested Capital (ROIC) | -2.57% |
| Return on Capital Employed (ROCE) | -4.53% |
| Weighted Average Cost of Capital (WACC) | 9.06% |
| Revenue Per Employee | 939,655 |
| Profits Per Employee | -143,179 |
| Employee Count | 85 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.60 |
Taxes
| Income Tax | -921,645 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is 0.86, so TSX:HLS's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 4.05 |
| 200-Day Moving Average | 4.47 |
| Relative Strength Index (RSI) | 35.25 |
| Average Volume (20 Days) | 85,355 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TSX:HLS had revenue of CAD 79.87 million and -12.17 million in losses. Loss per share was -0.39.
| Revenue | 79.87M |
| Gross Profit | 55.97M |
| Operating Income | -6.40M |
| Pretax Income | -13.09M |
| Net Income | -12.17M |
| EBITDA | 24.16M |
| EBIT | -6.40M |
| Loss Per Share | -0.39 |
Balance Sheet
The company has 19.50 million in cash and 59.51 million in debt, with a net cash position of -40.01 million or -1.29 per share.
| Cash & Cash Equivalents | 19.50M |
| Total Debt | 59.51M |
| Net Cash | -40.01M |
| Net Cash Per Share | -1.29 |
| Equity (Book Value) | 78.44M |
| Book Value Per Share | 2.51 |
| Working Capital | 2.02M |
Cash Flow
In the last 12 months, operating cash flow was 25.92 million and capital expenditures -137,750, giving a free cash flow of 25.78 million.
| Operating Cash Flow | 25.92M |
| Capital Expenditures | -137,750 |
| Depreciation & Amortization | 29.79M |
| Net Borrowing | -18.15M |
| Free Cash Flow | 25.78M |
| FCF Per Share | 0.83 |
Margins
Gross margin is 70.07%, with operating and profit margins of -8.02% and -15.24%.
| Gross Margin | 70.07% |
| Operating Margin | -8.02% |
| Pretax Margin | -16.39% |
| Profit Margin | -15.24% |
| EBITDA Margin | 30.24% |
| EBIT Margin | -8.02% |
| FCF Margin | 33.11% |
Dividends & Yields
TSX:HLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.42% |
| Shareholder Yield | 1.42% |
| Earnings Yield | -10.93% |
| FCF Yield | 23.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for TSX:HLS is 7.32, which is 97.84% higher than the current price. The consensus rating is "Buy".
| Price Target | 7.32 |
| Price Target Difference | 97.84% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 12.32% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TSX:HLS has an Altman Z-Score of -1.02 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.02 |
| Piotroski F-Score | 4 |